Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Neuroectodermal Tumors, Primitive × Capecitabine × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 348 Colorectal Neoplasms 261 Rectal Neoplasms 193 Stomach Neoplasms 175 Pancreatic Neoplasms 109 Neoplasm Metastasis 107 Colonic Neoplasms 77 Neoplasms 73 Triple Negative Breast Neoplasms 53 Esophageal Neoplasms 50 Nasopharyngeal Carcinoma 32 Biliary Tract Neoplasms 32 Gallbladder Neoplasms 28 Cholangiocarcinoma 28 Adenocarcinoma 28 Carcinoma, Hepatocellular 25 Bile Duct Neoplasms 20 Adenocarcinoma Of Esophagus 19 Locally Advanced Rectal Cancer 17 Brain Neoplasms 17 Colorectal Cancer Metastatic 15 Liver Neoplasms 14 Esophageal Squamous Cell Carcinoma 14 Carcinoma, Non-Small-Cell Lung 14 Squamous Cell Carcinoma of Head and Neck 13 Parkinson Disease 4, Autosomal Dominant Lewy Body 13 Head and Neck Neoplasms 13 Gastrointestinal Neoplasms 13 Ovarian Neoplasms 12 Anus Neoplasms 12

Interventions

Temozolomide 9 Cyclophosphamide 6 Radiotherapy 5 antineoplaston AS 2-1 4 antineoplaston A10 4 Magnetic Resonance Spectroscopy 4 Filgrastim 4 Etoposide 4 Cisplatin 4 Melphalan 3 Carmustine 3 Carboplatin 3 sargramostim 2 gallium Ga 68 dotatate 2 fludarabine 2 dactolisib 2 Vincristine 2 Thiotepa 2 Surveys and Questionnaires 2 Paclitaxel 2 Irinotecan 2 Gemcitabine 2 Gadolinium DTPA 2 Everolimus 2 Donepezil 2 Biopsy 2 Bevacizumab 2 Automobiles 2 veliparib 1 trametinib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02358356 2022-07-05

CONTROL NETS

Australasian Gastro-Intestinal Trials Group

Phase 2 Completed

Neuroectodermal Tumors, Primitive

Data powered by HemOnc (CC BY 4.0) Colophon ⚡